Dasatinib Anhydrous

CHEMBL1421 Phase 4 अनुमोदित Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

488.0 g/mol

LogP

3.6

Phase

4

The anhydrous crystal form of dasatinib, a BCR-ABL tyrosine kinase inhibitor used for CML and Ph+ ALL. The anhydrous form represents a specific polymorphic crystal structure used in pharmaceutical manufacturing.

आणविक भार

488.0000 g/mol

LogP

3.60

TPSA

135.00 Å²

लिपिंस्की RO5

उत्तीर्ण

चिकित्सीय क्षेत्र

Pancreatic Cancer Lymphoma Breast Cancer Prostate Cancer Leukemia

क्रिया का तंत्र

Selectively inhibits specific receptor tyrosine kinases involved in tumor cell proliferation, angiogenesis, and survival signaling. By blocking ATP binding to the kinase domain, it prevents phosphorylation cascades that drive cancer cell growth.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

तंत्र

Selectively inhibits specific receptor tyrosine kinases involved in tumor cell proliferation, angiogenesis, and survival signaling. By blocking ATP binding to the kinase domain, it prevents phosphorylation cascades that drive cancer …

2D संरचना

SVG PNG

Cite this structure

Embed this structure

SMILES

Cc1nc(Nc2ncc(C(=O)Nc3c(C)cccc3Cl)s2)cc(N2CCN(CCO)CC2)n1

InChI

InChI=1S/C22H26ClN7O2S/c1-14-4-3-5-16(23)20(14)28-21(32)17-13-24-22(33-17)27-18-12-19(26-15(2)25-18)30-8-6-29(7-9-30)10-11-31/h3-5,12-13,31H,6-11H2,1-2H3,(H,28,32)(H,24,25,26,27)

Molecular Formula

C22H26ClN7O2S

HBD / HBA

3 / 9

घूर्णनीय बंधन

7

भारी परमाणु

33

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

अक्सर पूछे जाने वाले प्रश्न

The anhydrous crystal form of dasatinib, a BCR-ABL tyrosine kinase inhibitor used for CML and Ph+ ALL. The anhydrous form represents a specific polymorphic crystal structure used in pharmaceutical manufacturing.

Selectively inhibits specific receptor tyrosine kinases involved in tumor cell proliferation, angiogenesis, and survival signaling. By blocking ATP binding to the kinase domain, it prevents phosphorylation cascades that drive cancer cell growth.

Yes, Dasatinib Anhydrous is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1421. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 3062316. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

PillFYI

रोगी-अनुकूल जानकारी खोज रहे हैं?

Dasatinib Anhydrous PillFYI पर

संरचना

त्वरित डेटा

सूत्र: C22H26ClN7O2S

बाहरी लिंक

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

चिकित्सा अस्वीकरण

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.